SCHEMBL12875682

SCHEMBL12875682

Cc1cccc(-c2csc(Cn3cc(C(=O)O)cn3)n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 2/20 0.44
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
ATP4A P20648 2/20 0.41
ATP4B P51164 2/20 0.41
KMO O15229 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
AKT1 P31749 1/20 0.41
RAB9A P51151 3/20 0.40
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
KDM4E B2RXH2 3/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875705 0.91 ATP4A (0.46) PDE3BPDE3AATP4AATP4BAKT1
SCHEMBL1198883 0.89 EIF4E (0.46) HDAC3HDAC8HDAC6RAB9AALDH1A1
SCHEMBL1199302 0.89 HDAC3 (0.44) KMOHDAC3HDAC8HDAC6RAB9A
SCHEMBL27827176 0.88 TSHR (0.44) HDAC3HDAC8HDAC6RAB9AALDH1A1
SCHEMBL12875680 0.88 L3MBTL1 (0.44) PDE3BPDE3AATP4AATP4BAKT1
SCHEMBL12876399 0.88 RAB9A (0.53) SIRT5AKT1RAB9AALDH1A1L3MBTL1
SCHEMBL1198915 0.88 RAB9A (0.51) HDAC3HDAC8HDAC6AKT1RAB9A
SCHEMBL1199156 0.87 KDM4E (0.49) SIRT5PDE3BPDE3AKMOHDAC3
SCHEMBL1198214 0.87 EGLN1 (0.47) PDE3BPDE3AATP4AATP4BKMO
SCHEMBL27827177 0.87 CSNK2A2 (0.51) HDAC3HDAC8HDAC6RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A SIRT5 531/4885PDE3B 1/4885PDE3A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.